Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.
DAPSA
Impact of disease
MDA
PsAID
Psoriatic arthritis
Remission
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
28
12
2019
accepted:
27
03
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Patient-reported outcomes measures, such as those provided by the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, have been found to be a reliable indicator of change during treatment, predictive of long-term outcomes, and the impact of psoriatic arthritis (PsA) on patients' lives. The objective of the study was to describe the demographic and clinical characteristics of PsA patients with a low disease impact and to analyze predictive factors for that state. Post hoc analysis of a cross-sectional multicenter study that included 223 consecutive patients. PsAID questionnaire was used to estimate disease impact. Patients with a PsAID < 4 were considered in low disease impact. Minimal disease activity (MDA) response and the Health Assessment Questionnaire (HAQ) were also assessed. The degree of agreement between the different outcomes was addressed by Cohen's kappa index. One hundred and twenty-two (54.7%) patients reached a PsAID < 4. Among them, 52.0% and 68.0% presented articular or skin remission, respectively. Almost 75% of patients were in MDA state and 85.2% presented a low disability state according to the HAQ. A moderate concordance between HAQ ≤ 0.5 and PsAID < 4 (k = 0.53), fair between MDA and PsAID < 4 (k = 0.36), and moderate between DAPSA remission and PsAID < 4 (k = 0.46) was observed. Multivariate logistic regression analysis showed that patients with distal interphalangeal joint (DIP) disease (OR 0.40, 95%CI, 0.20-0.79, p = 0.009), family history of PsA (OR 0.25, 95%CI, 0.09-0.72, p = 0.010), and higher C-reactive protein (OR 0.92, 95%CI, 0.85-0.99, p = 0.036) were significantly less likely to reach a PsAID < 4. There is certain discrepancy between disease activity measures and a low impact of disease in PsA. Clinical features (DIP joint involvement), biologic activity, and genetic factors (familial history) seem to be associated with lower odds of reaching a low disease impact.
Sections du résumé
BACKGROUND
Patient-reported outcomes measures, such as those provided by the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, have been found to be a reliable indicator of change during treatment, predictive of long-term outcomes, and the impact of psoriatic arthritis (PsA) on patients' lives. The objective of the study was to describe the demographic and clinical characteristics of PsA patients with a low disease impact and to analyze predictive factors for that state.
METHODS
Post hoc analysis of a cross-sectional multicenter study that included 223 consecutive patients. PsAID questionnaire was used to estimate disease impact. Patients with a PsAID < 4 were considered in low disease impact. Minimal disease activity (MDA) response and the Health Assessment Questionnaire (HAQ) were also assessed. The degree of agreement between the different outcomes was addressed by Cohen's kappa index.
RESULTS
One hundred and twenty-two (54.7%) patients reached a PsAID < 4. Among them, 52.0% and 68.0% presented articular or skin remission, respectively. Almost 75% of patients were in MDA state and 85.2% presented a low disability state according to the HAQ. A moderate concordance between HAQ ≤ 0.5 and PsAID < 4 (k = 0.53), fair between MDA and PsAID < 4 (k = 0.36), and moderate between DAPSA remission and PsAID < 4 (k = 0.46) was observed. Multivariate logistic regression analysis showed that patients with distal interphalangeal joint (DIP) disease (OR 0.40, 95%CI, 0.20-0.79, p = 0.009), family history of PsA (OR 0.25, 95%CI, 0.09-0.72, p = 0.010), and higher C-reactive protein (OR 0.92, 95%CI, 0.85-0.99, p = 0.036) were significantly less likely to reach a PsAID < 4.
CONCLUSIONS
There is certain discrepancy between disease activity measures and a low impact of disease in PsA. Clinical features (DIP joint involvement), biologic activity, and genetic factors (familial history) seem to be associated with lower odds of reaching a low disease impact.
Identifiants
pubmed: 32295620
doi: 10.1186/s13075-020-02168-1
pii: 10.1186/s13075-020-02168-1
pmc: PMC7161121
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Investigateurs
Carlos Montilla
(C)
Miguel Angel Abad
(MA)
Juan Carlos Torre-Alonso
(JC)
Jose Andrés Román-Ivorra
(JA)
Jesús Sanz
(J)
Juan Salvatierra
(J)
Jaime Calvo-Alén
(J)
Agustín Sellas
(A)
Fernando José Rodriguez
(FJ)
Alberto Bermúdez
(A)
Manuel Romero
(M)
Manuel Riesco
(M)
Juan Carlos Cobeta
(JC)
Fermín Medina
(F)
M Luz García
(ML)
Ana Urruticoechea
(A)
Carlos González
(C)
E Judez
(E)
Beatriz González
(B)
Pilar Fernández
(P)
Lucía Pantoja
(L)
Rosa Morlá
(R)
Références
Ann Rheum Dis. 2019 Feb;78(2):201-208
pubmed: 30442648
Ann Rheum Dis. 2010 Jan;69(1):48-53
pubmed: 19147615
Clin Rheumatol. 2007 Mar;26(3):330-4
pubmed: 16622591
Joint Bone Spine. 2019 Mar;86(2):269-270
pubmed: 30362458
Ann Rheum Dis. 2014 Jun;73(6):1012-9
pubmed: 24790067
Arthritis Care Res (Hoboken). 2015 May;67(6):842-7
pubmed: 25469741
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Semin Arthritis Rheum. 2018 Apr;47(5):654-665
pubmed: 29037523
Ann Rheum Dis. 2016 May;75(5):811-8
pubmed: 26269398
Arthritis Care Res (Hoboken). 2019 Oct 14;:
pubmed: 31609525
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1606-1611
pubmed: 27998026
Arthritis Rheum. 2007 Mar;56(3):840-9
pubmed: 17328058
Arthritis Rheum. 2012 Sep;64(9):2814-23
pubmed: 22810704
Ann Rheum Dis. 2018 Mar;77(3):343-347
pubmed: 29146740
Arthritis Rheum. 1995 Jun;38(6):845-50
pubmed: 7779129
J Rheumatol. 2017 Oct;44(10):1522-1528
pubmed: 28148697
J Rheumatol. 2014 May;41(5):1011-5
pubmed: 24584919
Clin Rheumatol. 2018 Mar;37(3):661-666
pubmed: 29380165
Reumatol Clin. 2016 Nov - Dec;12(6):307-312
pubmed: 26830438
Arthritis Res Ther. 2017 Mar 29;19(1):72
pubmed: 28356155
Rheumatology (Oxford). 2018 Feb 1;57(2):283-290
pubmed: 28541484
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
J Pain Symptom Manage. 2016 May;51(5):933-937.e2
pubmed: 26740387
Ann Rheum Dis. 2018 Jan;77(1):3-17
pubmed: 28684559
Semin Arthritis Rheum. 2019 Oct;49(2):241-245
pubmed: 31101369
Clin Exp Rheumatol. 2019 Sep-Oct;37(5):808-812
pubmed: 30767863